Last Updated: June 23, 2026

Patent: 5,595,739


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,595,739
Title:Hepatitis B virus mutants, reagents and methods for detection
Abstract:Mutant Hepatitis B Virus (HBV) nucleic acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HBV nucleic acid sequences, HBV immunogenic particles, and a method for producing antibodies to HBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HBV nucleic acid sequences.
Inventor(s):William F. Carman, Richard H. Decker, Lesley Wallace, Larry T. Mimms, Larry R. Solomon
Assignee: University of Glasgow , Abbott Laboratories
Application Number:US08/059,031
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 5,595,739: Claims and US Patent Landscape Analysis

What does US 5,595,739 claim, and what is the technical scope?

US Patent 5,595,739 is a US patent with an issue date of Jan. 21, 1997. The available public record for this patent does not provide sufficient detail in the information provided here to reconstruct: (1) the independent claim set, (2) claim terms, (3) the critical claim limitations, (4) the specification’s stated objectives, or (5) the prosecution history that would anchor a claim-construction map.

Because a complete, accurate claims-based and landscape-based analysis requires exact claim language (at minimum the independent claims and key dependent claims) and verifiable bibliographic/technology descriptors, no complete or defensible claim chart or freedom-to-operate risk map can be produced from the information available in this session.

What claims are likely to be enforceable, and where are the legal pressure points?

A meaningful enforceability and validity-risk analysis depends on the claim structure and wording, including:

  • Whether the independent claims use functional language (and how it is tied to embodiments),
  • Whether the claims rely on means-plus-function limitations (35 U.S.C. § 112(f) implications),
  • Whether the novelty turns on a specific component architecture, a process sequence, or a parameter range,
  • Whether the specification supports those limitations with adequate description.

No claim text is provided here, so enforceability pressure points cannot be identified without risking factual fabrication.

What is the US patent landscape around the same technical concept?

A landscape analysis requires at least one of the following: the patent’s technology keywords, classification codes, inventors/assignees, cited references, or the relevant claim themes that define the search set. In this session, none of those inputs are available in a way that supports an accurate search narrative or a quantified landscape.

As a result, it is not possible to produce a defensible map of:

  • Closest prior art by classification and citation adjacency,
  • Competitive families (continuations, divisionals, or international equivalents),
  • Invalidation likelihood drivers (anticipation vs. obviousness paths),
  • Post-1997 settlement or licensing activity markers (if any),
  • Design-around patterns that can be inferred from claim variations in later filings.

Who is positioned against this patent, and what are likely competitive design-arounds?

Competitive positioning analysis requires:

  • The assignee and who continued related filings after issuance,
  • The active claim scope and how later patents narrow or shift limitations,
  • Evidence from later prosecution outcomes or claim amendments.

None of these are present here in verifiable form. Any attempt to name competitors, propose design-arounds, or infer licensing posture would be speculative.

How strong is the validity posture in view of likely prior art?

Validity risk analysis typically targets:

  • Anticipation: a single reference matching every element,
  • Obviousness: combinations supported by motivation and routine substitution,
  • 112 issues: indefiniteness, lack of written description, lack of enablement,
  • Double patenting: particularly if continuations exist.

This requires cited references, claim language, and specification support. Those are not available in the provided information, so the analysis cannot be completed.

What are the most business-relevant takeaways for R&D, licensing, or investment?

A claims-and-landscape decision-quality assessment cannot be completed without the actual claim text and the bibliographic record tied to the technology.

Key takeaways (based strictly on available information):

  • US 5,595,739 exists and issued Jan. 21, 1997.
  • The session does not include the claim text, cited art, assignee/inventor metadata, CPC/US classification, or prosecution history needed for a complete landscape.
  • No defensible conclusions on claim scope, validity, or competitive positioning can be produced without those data.

Key Takeaways

  • No claim-level scope can be reconstructed from the information available here, so enforceability and validity-risk analysis cannot be completed.
  • No landscape can be quantified (closest prior art, citation adjacency, competitor families, or design-arounds) without bibliographic and claim/keyword inputs.
  • The only confirmed data point in this session is US 5,595,739 issue date: Jan. 21, 1997.

FAQs

  1. What is the issue date of US 5,595,739?
    Jan. 21, 1997.

  2. Can I extract claim scope from this analysis alone?
    No. The claim text and specification mapping are not provided in the available record for this session.

  3. Does this patent have a known assignee or inventors in this session?
    Not included in the available information here.

  4. Can validity risks (anticipation/obviousness/112) be assessed from this session?
    No. That requires claim language and cited references.

  5. Can I identify competitive patents and likely design-arounds from this session?
    No. That requires classification/keywords and a source-based search record.


References

[1] United States Patent 5,595,739 (issue date Jan. 21, 1997).

More… ↓

⤷  Start Trial

Details for Patent 5,595,739

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Wyeth Pharmaceuticals Llc XYNTHA, XYNTHA SOLOFUSE antihemophilic factor (recombinant), plasma/albumin free For Injection 125264 February 21, 2008 5,595,739 2014-01-21
Wyeth Pharmaceuticals Llc XYNTHA, XYNTHA SOLOFUSE antihemophilic factor (recombinant), plasma/albumin free For Injection 125264 August 06, 2010 5,595,739 2014-01-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.